A Q&A With Lilly Biomedicines President Christi Shaw

The Eli Lilly & Co. executive talked with Scrip about the competitive dynamics facing Taltz, the status of baricitinib and launching galcanezumab in the crowded CGRP class, as well as about industry issues like drug rebates, drug pricing and gender diversity.

Christi Shaw
Lilly Biomedicines President Christi Shaw

Eli Lilly & Co. Bio-Medicines President Christi Shaw has been at the company for over a year now, responsible for the big pharma's commercial portfolio excluding diabetes and oncology. She stepped into the shoes previously filled by David Ricks, who moved up to lead the company as CEO, and is tasked with overseeing new drug launches in some of the industry's most competitive categories.

For example, she is overseeing the launch of the blockbuster contender Taltz (ixekizumab) for psoriasis and psoriatic arthritis, and will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip